by rvvadmin | Jan 17, 2022 | 2022
IRB approval to initiate Phase 2 study for methamphetamine abuse disorders Advancing psilocybin oral thin film, microneedle patch and biosynthesis programs TORONTO, Jan. 17, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV)...
by rvvadmin | Jan 6, 2022 | 2022
Approximately 700 subjects participated in the enrollment period Expected to begin subject enrollment in Turkey by mid-February Expected to complete enrollment in Q1-2022 TORONTO, Jan. 06, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB:...
by rvvadmin | Dec 29, 2021 | 2021
Screened approximately 700 subjects and expanding to Eastern Europe, including Turkey, as part of its clinical diversification plans to support global regulatory approvals No serious adverse events and safety concerns reported to date in the Phase 3 clinical trial...
by rvvadmin | Dec 3, 2021 | 2021
Expanding the potential of Bucillamine as an effective treatment for Omicron variant (B.1.1.529) Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta variant (B.1.617.2) Adding inflammatory markers along with viral load testing to current Phase 3...
by rvvadmin | Nov 23, 2021 | 2021
TORONTO, Nov. 23, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to...
